Other Name: interferon alpha-2a

Intefen is a recombinant human interferon alpha-2a product for the treatment of malignancies of the lymphatic or hematopoietic system, and viral infectious diseases, including adult chronic hepatitis B, acute and chronic hepatitis C and genital warts. Interferon is a protein that is produced naturally in the body in trace amounts. When exposed to viruses, certain cells produce interferon, which is released into the bloodstream or intercellular fluid to induce healthy cells to produce enzymes and proteins that counter and combat the infection. The anti-cellular or immuno-regulatory functions of interferon enable interferon products to play a central role against certain tumor and autoimmune diseases. Interferon alpha has been manufactured by pharmaceutical companies for therapeutic use against hairy-cell leukemia, hepatitis C and hepatitis B, as well as for treatment of genital warts and some rare cancers of the blood and bone marrow.

We obtained CFDA approval to manufacture and market Intefen in April 1995 and launched the product in December 1995. We believe that it was one of the first interferon alpha-2a products marketed in China. Intefen is manufactured at our bacterial cell-based production plant in Shenyang. Our Intefen products are available in lyophilized powder and injectable solution, each in three dosages: 1 MIU, 3 MIU and 5 MIU. Intefen is included in the National Medical Insurance Catalogue as a Category B drug.